Orthocell has appointed 12 US distributors for its nerve repair product Remplir™, well ahead of the expected target of 10 distributors by 30 June.
The Company’s distributor network now spans 21 states across the US, with each distributor specialising in nerve repair and holding direct relationships with surgeons and hospitals in their territories. This rapid expansion follows our US FDA clearance received last month and positions the Company for first sales in the US$1.6 billion nerve repair market this quarter.
The enthusiastic response from distributors demonstrates the quality of Remplir™ and confidence in its commercial potential. Our US team has established a robust management structure led by our VP of Sales and supported by four territory managers to maximise our market penetration.
Orthocell CEO and MD, Paul Anderson, said:
“It’s very pleasing to see such rapid progress on the expansion of our US distributor network so soon after receiving US FDA clearance in April. We’re well ahead of the targets we had set ourselves and expect that to translate to first US Remplir sales this quarter.”